http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
호텔 조직의 가치혁신문화가 지식공유와 서비스혁신행동에 미치는 영향에 관한 연구 - 특 1급 호텔 종사원을 중심으로 -
임소이,서원석 한국호텔리조트학회 2022 호텔리조트연구 Vol.21 No.5
This study proposes a measure of value innovation culture for rapidly changing hotel organizations and conducts a study on how organizations with such organizational culture affect knowledge sharing and service innovation behavior. Therefore, this study summarized the theoretical background of value innovation, organizational culture, definition of value innovation culture, and value innovation culture, and selected Khanapuri's 'Framework to assess Value Innovation Potential of organization' and set the measurement items as two sub-items. In addition, through a theoretical review of knowledge sharing and service innovation behavior, the hypothesis was clearly defined and a research model was established to conduct a survey. As a result, members of an organization with a culture of value innovation are determined to constantly try to reach a consensus on innovative ideas, modify and supplement new ideas to work, try to share job information or knowledge within the hotel, and find new skills, tools, and intentions. Based on these research results, the direction of research tasks for future research was suggested along with theoretical and practical implications.
임소이,김윤환,이광범,이종민 대한부인종양학회 2018 Journal of Gynecologic Oncology Vol.29 No.5
Objective: To determine whether drospirenone/estradiol (DRSP/E2) has an adverse effect on clinical outcomes in surgically staged International Federation of Gynecology and Obstetrics (FIGO) stage I/II endometrial cancer (EC) patients. Methods: In a retrospective case-controlled study, 58 women with EC who had received DRSP/E2 postoperatively were compared with 116 women who had not. And, oncologic safety of postoperative hormone therapy with DRSP/E2 in EC survivors were compared between the 2 groups after propensity score matching using a logistic regression model. Results: The median ages were 47.7 years and 53.6 years for the study and the control groups, respectively (p<0.001). The study group had similar parity (p=0.71), lower body mass index (p=0.03) and more premenopausal women (p<0.001) than the control group. The stages were completely matched. The grades (p=0.42), lymphovascular space invasion (p=0.23), preoperative cancer antigen 125 (CA 125) level (p=0.89), and hormone receptor status (p=0.07) were similar in both groups. The median tumor diameter was statistically larger in the study group than in the control group (p<0.001). Both group received similar adjuvant therapy (p=0.80). In the propensity matching, only hormone receptor status was significantly different (p=0.03). In the univariate analysis, only stage was significantly associated with disease-free survival (DFS) and there was no variable associated with overall survival (OS). And, there was no significant factor identified in multivariate analysis. The difference in the DFS (p=0.63) and in the OS (p=0.32) was not significant. The same results were obtained after propensity score matching. Conclusion: Postoperative hormone therapy with DRSP/E2 in EC survivors did not increase recurrence or the death rate.